Roivant Sciences Ltd (ROIV)

May 29, 2025, 2:17 PM EDT - 8 days ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 8 days ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 22 days ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 6 weeks ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 6 weeks ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 2 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 2 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 3 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 4 months ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 4 months ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 4 months ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 4 months ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 4 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 5 months ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 6 months ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 6 months ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 7 months ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 7 months ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 8 months ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 9 months ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 9 months ago

Roivant Flips a Skin Drug to Organon

OGN

Sep 18, 2024, 7:30 AM EDT - 9 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Sep 10, 2024, 6:30 AM EDT - 9 months ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 9 months ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 9, 2024, 12:54 PM EDT - 9 months ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Sep 9, 2024, 7:00 AM EDT - 9 months ago

Roivant Provides Update on Graves' Disease Development Program

Aug 30, 2024, 8:00 AM EDT - 10 months ago

Top Stocks Near Their 200-Day SMA

CCL CUK SM

Aug 22, 2024, 1:00 AM EDT - 10 months ago

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Aug 9, 2024, 12:03 PM EDT - 10 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 2, 2024, 7:27 AM EDT - 1 year ago

Roivant Sciences: Executing On Huge Buyback Program With More To Come

May 30, 2024, 12:23 PM EDT - 1 year ago

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 16, 2024, 4:05 PM EDT - 1 year ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis

Apr 2, 2024, 7:28 AM EDT - 1 year ago

Roivant's anti-inflammatory drug succeeds in mid-stage study

Apr 2, 2024, 7:00 AM EDT - 1 year ago

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

Mar 18, 2024, 3:52 PM EDT - 1 year ago

Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success

Feb 13, 2024, 12:02 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript

Feb 13, 2024, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

Jan 7, 2024, 1:15 PM EST - 1 year ago

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy

Dec 20, 2023, 4:30 PM EST - 1 year ago

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 9:00 AM EST - 1 year ago

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Nov 27, 2023, 8:52 AM EST - 1 year ago

Roivant Sciences shares drop as lupus treatment misses trial goal

Nov 27, 2023, 8:49 AM EST - 1 year ago

Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study

Nov 13, 2023, 7:19 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 1 year ago

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Oct 30, 2023, 5:30 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Oct 24, 2023, 3:19 PM EDT - 1 year ago

A biotech firm founded by Vivek Ramaswamy turned $15 million into $5 billion by flipping a bowel-disease treatment that Pfizer gave it for free

PFE

Oct 24, 2023, 9:25 AM EDT - 1 year ago

Roivant Sciences: Risk-Transforming Deal Met With Crickets